BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25749522)

  • 21. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
    Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
    Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
    Pettus LH; Andrews KL; Booker SK; Chen J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS; Wang HL
    J Med Chem; 2016 Jul; 59(13):6407-30. PubMed ID: 27285051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes.
    El-Miligy MMM; Al-Kubeisi AK; El-Zemity SR; Nassra RA; Abu-Serie MM; Hazzaa AA
    Bioorg Chem; 2021 Oct; 115():105171. PubMed ID: 34303896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
    Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
    Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
    Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel Cinnamon-Related Natural Product with Pim-1 Inhibitory Activity Inhibits Leukemia and Skin Cancer.
    Kim JE; Son JE; Jeong H; Joon Kim D; Seo SK; Lee E; Lim TG; Kim JR; Chen H; Bode AM; Lee KW; Dong Z
    Cancer Res; 2015 Jul; 75(13):2716-2728. PubMed ID: 25948588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-18, a stemonamide synthetic intermediate inhibits Pim kinase activity and induces cell apoptosis, acting as a potent anticancer drug.
    Wang Z; Li XM; Shang K; Zhang P; Wang CF; Xin YH; Zhou L; Li YY
    Oncol Rep; 2013 Mar; 29(3):1245-51. PubMed ID: 23314349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts.
    Santio NM; Eerola SK; Paatero I; Yli-Kauhaluoma J; Anizon F; Moreau P; Tuomela J; Härkönen P; Koskinen PJ
    PLoS One; 2015; 10(6):e0130340. PubMed ID: 26075720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
    Bataille CJ; Brennan MB; Byrne S; Davies SG; Durbin M; Fedorov O; Huber KV; Jones AM; Knapp S; Liu G; Nadali A; Quevedo CE; Russell AJ; Walker RG; Westwood R; Wynne GM
    Bioorg Med Chem; 2017 May; 25(9):2657-2665. PubMed ID: 28341403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
    Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
    J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel (+)-Usnic acid derivatives as potential anti-leukemia agents with pan-Pim kinases inhibitory activity.
    Wang S; Zang J; Huang M; Guan L; Xing K; Zhang J; Liu D; Zhao L
    Bioorg Chem; 2019 Aug; 89():102971. PubMed ID: 31200288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIM kinases as therapeutic targets against advanced melanoma.
    Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
    Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-based design of low-nanomolar PIM kinase inhibitors.
    Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
    Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
    Martínez-González S; Rodríguez-Arístegui S; Gómez de la Oliva CA; Hernández AI; González Cantalapiedra E; Varela C; García AB; Rabal O; Oyarzabal J; Bischoff JR; Klett J; Albarrán MI; Cebriá A; Ajenjo N; García-Serelde B; Gómez-Casero E; Cuadrado-Urbano M; Cebrián D; Blanco-Aparicio C; Pastor J
    Eur J Med Chem; 2019 Apr; 168():87-109. PubMed ID: 30802730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of 4,6-Disubstituted Pyrido[3,2-
    Han Y; Zhang H; Wang S; Li B; Xing K; Shi Y; Cao H; Zhang J; Tong T; Zang J; Guan L; Gao X; Wang Y; Liu D; Huang M; Jing Y; Zhao L
    J Med Chem; 2021 Sep; 64(18):13719-13735. PubMed ID: 34515481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family.
    Quevedo CE; Bataille CJR; Byrne S; Durbin M; Elkins J; Guillermo A; Jones AM; Knapp S; Nadali A; Walker RG; Wilkinson IVL; Wynne GM; Davies SG; Russell AJ
    Bioorg Med Chem; 2020 Nov; 28(22):115724. PubMed ID: 33128909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PIM1 kinase inhibitors induce radiosensitization in non-small cell lung cancer cells.
    Kim W; Youn H; Kwon T; Kang J; Kim E; Son B; Yang HJ; Jung Y; Youn B
    Pharmacol Res; 2013 Apr; 70(1):90-101. PubMed ID: 23352980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease.
    Jackson LJ; Pheneger JA; Pheneger TJ; Davis G; Wright AD; Robinson JE; Allen S; Munson MC; Carter LL
    Cell Immunol; 2012; 272(2):200-13. PubMed ID: 22078270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
    Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
    Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.